We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$127M
Cap. Flow %
-2.7%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Miscellaneous 1.94%
3 Industrials 1.1%
4 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
126
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$206K ﹤0.01%
18,023
– –
ALKS icon
127
Alkermes
ALKS
$7.52B
– –
-151,400
Closed -$4.74M
BAX icon
128
CALL
Baxter International
BAX
$12.3B
– –
-300,000
Closed -$13.7M
BMY icon
129
Bristol-Myers Squibb
BMY
$130B
– –
-1,488,000
Closed -$95.2M
EW icon
130
Edwards Lifesciences
EW
$49.4B
– –
-515,000
Closed -$48.6M
FOLD
131
DELISTED
Amicus Therapeutics
FOLD
– –
-1,856,400
Closed -$23.3M
GHRS icon
132
GH Research
GHRS
$1.87B
– –
-736,315
Closed -$8.74M
HUM icon
133
CALL
Humana
HUM
$47.3B
– –
-25,000
Closed -$11.2M
MRSN
134
CALL
DELISTED
Mersana Therapeutics
MRSN
– –
-10,000
Closed -$823K
MRSN
135
DELISTED
Mersana Therapeutics
MRSN
– –
-288,597
Closed -$23.7M
NKTR icon
136
CALL
Nektar Therapeutics
NKTR
$2.27B
– –
-34,333
Closed -$296K
TGTX icon
137
CALL
TG Therapeutics
TGTX
$8.18B
– –
-45,800
Closed -$1.14M
THC icon
138
CALL
Tenet Healthcare
THC
$21B
– –
-100,000
Closed -$8.14M
TSVT
139
DELISTED
2seventy bio
TSVT
– –
-2,391,628
Closed -$24.2M
TVTX icon
140
Travere Therapeutics
TVTX
$5.85B
– –
-2,118,100
Closed -$32.5M
ZBH icon
141
Zimmer Biomet
ZBH
$18.7B
– –
-245,000
Closed -$35.7M
RVNC
142
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-100,000
Closed -$2.53M
DBTX
143
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
– –
-4,945,192
Closed -$19M
VECT
144
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-5,156,561
Closed -$87.7M
HZNP
145
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-50,000
Closed -$5.14M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.